)
Byhealth (300146) investor relations material
Byhealth Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Operating income for Jan–Sept 2025 was RMB 4.92 billion, down 14.27% year-over-year; net profit attributable to shareholders rose 4.45% to RMB 907 million for the same period.
Third quarter single-quarter revenue and net profit both achieved year-over-year growth despite a challenging consumption environment and fierce competition.
Strategic focus included innovation in core product categories, omni-channel quality and efficiency, and digitalization.
Financial highlights
Q3 operating income: RMB 1.38 billion, up 23.45% compared to the previous quarter.
Q3 net profit attributable to shareholders: RMB 171 million, up 861.91% sequentially.
Basic and diluted EPS for Jan–Sept 2025: RMB 0.53, up 3.92% year-over-year.
Net cash flow from operating activities for Jan–Sept 2025: RMB 921 million, up 170.13% year-over-year.
Total assets at period end: RMB 14.00 billion; owner's equity: RMB 11.31 billion.
Outlook and guidance
Continued focus on operating quality improvement, product innovation, and digital transformation to drive future growth.
- TimeTickerHeadlineOpen
- CMBT
Q1 profit, Golden Ocean merger, and decarbonization drive strong outlook. - CBT
Adjusted EPS down 13% to $1.53 as Battery Materials growth offset Reinforcement Materials decline. - ADVENZYMES
Q3 FY26 revenue up 2% YoY, PAT up 11%, with wind power SPV investment approved. - SIMO
Q4 2025 revenue and margins surged on SSD, eMMC/UFS, and automotive growth; 2026 outlook strong. - FSV
Annual revenue up 5% to $5.50B; Adjusted EBITDA and EPS both saw double-digit growth. - QLINEA
Over 400% revenue growth in 2025, with US expansion and breakeven targeted for 2027. - OMV
Clean CCS Operating Result down 10% year-over-year, with strong cash flow and 9.3% dividend yield. - UPM
Strong Q4 cash flow and strategic moves support growth despite lower sales and EBIT. - GSK
7% sales growth and 12% EPS rise, led by Specialty and HIV, with strong 2026 outlook. - UBSG
Net profit surged 56% YoY, with accelerated capital repatriation and robust capital ratios.
Next Byhealth earnings date
Next Byhealth earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)